29006-02-8

Basic information

• Product Name: 4-methoxybutyric acid
• Synonyms: Einecs 249-366-5;4-methoxybutyric acid;4-Methoxybutanoic acid
• CAS NO: 29006-02-8
• Molecular Formula: C₅H₁₀O₃
• Molecular Weight: 118.1311
• EINECS: 249-366-5
• Mol File: 29006-02-8.mol

Chemical Properties

• Boiling Point: 218.4 °C at 760 mmHg
• Flash Point: 91.6 °C
• Appearance: /
• Density: 1.054 g/cm³
• Vapor Pressure: 0.0478mmHg at 25°C
• Refractive Index: 1.422
• CAS DataBase Reference: 4-methoxybutyric acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methoxybutyric acid(29006-02-8)
• EPA Substance Registry System: 4-methoxybutyric acid(29006-02-8)

Safety Data

• Hazardous Substances Data: 29006-02-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-methoxybutyric acid is used as an intermediate in the synthesis of various drugs and bioactive compounds for its ability to enhance the antimicrobial and anti-inflammatory properties of pharmaceutical formulations.
Used in Perfume Industry:
4-methoxybutyric acid is used as a fragrance ingredient for its fruity odor, contributing to the creation of unique and appealing scents in perfumes and other fragranced products.
Used in Agricultural Chemicals:
4-methoxybutyric acid is used as a component in the development of agricultural chemicals, leveraging its antimicrobial properties to protect crops and enhance agricultural productivity.
Used in Organic Chemistry:
4-methoxybutyric acid is used as a versatile building block in organic chemistry for its ability to be incorporated into a wide range of chemical reactions and the synthesis of various compounds, making it a valuable asset in the development of new chemical products.

InChI:InChI=1/C5H10O3/c1-8-4-2-3-5(6)7/h2-4H2,1H3,(H,6,7)

Upstream product

• 57371-37-6 4-methoxy-1-butyronitrile 
• 75933-65-2 4-methoxycrotonic acid 
• 6335-02-0 ethyl methoxyethylmalonate 
• 35841-35-1 β-Methoxyethylmalonsaeure 
• 133604-78-1 3,5-dimethylphenyl 4-methoxybutyrate 
• 77-78-1 dimethyl sulfate 
• 96-48-0 4-butanolide 
• 67-56-1 methanol 
• 29006-01-7 Methyl 4-methoxybutyrate 
• 111-32-0 4-methoxybutanol 

Downstream Products

• 3153-37-5 methyl 4-chlorobutyrate 
• 38624-41-8 4-methoxy-1-phenylbutan-1-ol 
• 17429-05-9 6-methoxy-2-methyl-hexan-3-one 
• 90749-78-3 N-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4-methoxy-butyramide 
• 90749-80-7 N-(6-Amino-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4-methoxy-butyramide 
• 90749-83-0 N-(6-Amino-3-methyl-2,4-dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4-methoxy-butyramide 
• 133604-78-1 3,5-dimethylphenyl 4-methoxybutyrate 
• 146008-46-0 (1S,3S,4S,5R,6R,7R)-1-((4S,5R)-4-Acetoxy-5-methyl-3-methylene-6-phenyl-hexyl)-4-hydroxy-6-(4-methoxy-butyryloxy)-7-(1-methoxy-1-methyl-ethoxy)-2,8-dioxa-bicyclo[3.2.1]octane-3,4,5-tricarboxylic acid tri-tert-butyl ester 
• 928163-26-2 N-((1R,2R)-2-hydroxy-1-methyl-2-phenylethyl)-4-methoxy-N-methylbytyramide 
• 928163-27-3 (R)-N-((1R,2R)-2-hydroxy-1-methyl-2-phenylethyl)-4-methoxy-2,N-dimethylbytyramide 
• 443688-50-4 2-bromo-4-methoxy-butyric acid 2,6-dimethoxy-phenyl ester 
• 90749-97-6 8-(3-Methoxy-propyl)-1-methyl-3-phenyl-3,7-dihydro-purine-2,6-dione 
• 90749-98-7 8-(3-Methoxy-propyl)-1,7-dimethyl-3-phenyl-3,7-dihydro-purine-2,6-dione 
• 17429-04-8 5-methoxy-2-pentanone 

Relevant articles and documents

Directed γ-C(sp3)-H Alkylation of Carboxylic Acid Derivatives through Visible Light Photoredox Catalysis

Visible light photoredox catalysis enables direct γ- C(sp3)-H alkylation of saturated aliphatic carbonyl compounds. Electron-deficient alkenes are used as the coupling partners in this reaction. Distinguished site selectivity is controlled by the predominant 1,5-hydrogen atom transfer of an amidyl radical generated in situ.

2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS

The invention provides a compound which is a diazine of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt thereof, for use as an antifungal agent: (I) wherein X, N', C', A and E are as defined herein. The invention also provides a compound of Formula (I) as defined herein.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES

The present invention relates to compounds of formula (I) and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various diseases, such as allergic rhinitis.

Raf inhibitor compounds and methods of use thereof

Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Ether-directed palladium(II)-catalysed aza-Claisen rearrangements: studies on the origin of the directing effect

Four new chiral δ-substituted allylic trichloroacetimidates have been synthesised to probe the origin of the high diastereoselectivity observed for the MOM-ether directed palladium(II)-catalysed aza-Claisen rearrangement. Rearrangement of these compounds has not only provided strong evidence for this directing effect but also that during the rearrangement both oxygen atoms from the MOM-ether are involved in coordinating to and directing the palladium(II) catalyst.

Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.

ESTER DERIVATIVES OF RHEIN AND THEIR THERAPEUTIC USE

Compounds that may have anti-inflammatory activity are of general formula (I); wherein X1, is H or COR1, and X2 is H or COR2 but X1, and X2are not both H; R1 and R2 are the same or different and are each C1-4 alkyl substituted with R3, or a four to seven-membered ring which can be optionally substituted with R8 and can contain one or more additional heteroatoms selected from O, S(O)n and NR9; is R3 is F, CF3, OR4, NR5R6 O, S(O)n R7 ; R4, R5 and R6 are the same or different and are each H or C1-4 alkyl optionally substituted with R3, or NR5R6 is a C4-6 heterocycloalkyl ring containing one or more heteroatoms selected from O, NR8 and S(O)n; each n is 0-2; R7 is C1-4 alkyl; R8 is as defined for R3 or C1-4 alkyl optionally substituted with R3 or halogen; and R9 is H or C1-4 alkyl; or a salt, solvate or hydrate thereof.

Novel water soluble 2,6-dimethoxyphenyl ester derivatives with intravenous anaesthetic activity

A number of water soluble bis-amino-2,6-dimethoxyphenyl ester derivatives were found to exhibit improved anaesthetic activity in mice relative to propofol 1. Of the analogues disclosed, 44 was further profiled in rodents and found to be a superior agent to propofol for the induction and maintenance of anaesthesia.